Can the late prostate cancer be cured by taking Darolutamide?

In 2020, it is estimated that 1.4 million men will be diagnosed with prostate cancer, and about 375,000 people worldwide will die of prostate cancer. It has been two years now, and with the further growth of the global population, we have reason to believe that the number of this group will increase.
At the time of diagnosis, most men have localized prostate cancer, which means that their cancer is confined to the prostate and can be treated by radical surgery or radiotherapy.
When the disease recurs, it will transfer or spread. Androgen deprivation therapy (ADT) is the basis of treating hormone-sensitive diseases. Men with metastatic hormone-sensitive prostate cancer (HSPC) will start hormone therapy, such as ADT, ARi combined with ADT or docetaxel combined with ADT.
Even after receiving the above-mentioned first-line treatment, most patients with mHSPC will eventually progress to mCRPC, and their survival and quality of life will be seriously affected.

What medicine is dalotamide?

Dalotamide raw material is an androgen receptor inhibitor (ARi). Its unique chemical structure has high affinity for the receptor and shows strong antagonistic activity, thus inhibiting the function of the receptor and the growth of prostate cancer cells. So as to reduce the proliferation of prostate cancer cells in vitro and the tumor volume of prostate cancer transplanted tumor. It is suitable for the treatment of non-metastatic castration-resistant prostate cancer with high metastasis risk, and the overall survival rate of patients using this product in clinic has been significantly improved. The compound is also used in phase III ARASENS test for the treatment of metastatic hormone-sensitive prostate cancer.

What is the pharmacological action of dalotamide?

On July 30, 2019, the US Food and Drug Administration (FDA) approved the launch of a new anticancer oral tablet, Nubeqa (daruramide), for the treatment of patients with non-metastatic castration-tolerant prostate cancer (nmCRPC). It is a monoclonal antibody drug and can recognize and combine with HER2 receptor to form a complex. HER2 receptor is a member of human epidermal growth factor receptor (EGFR) family, which is involved in the regulation of cell growth, differentiation and survival in normal cells. However, in some patients with breast cancer and gastric cancer, the expression of HER2 receptor is too high, which leads to the proliferation, invasion and metastasis of cancer cells. Dalotamide tablets can block the signal transduction of HER2 receptor, thus inhibiting the growth and division of cancer cells.

How should we face the desperate situation?

Due to the continuous progress and development of medical technology, there will be more and more kinds of drugs that can be used for related diseases. As long as patients clearly understand the basic treatment measures, find the correct treatment principles, follow the doctor's requirements and step by step, they will solve the dilemma. However, in advanced prostate cancer, the focus has usually metastasized and spread, and the tumor can metastasize and destroy other tissues or organ structures. Patients with advanced prostate cancer have low cure rate, short survival period and few treatment methods. At this time, even if they actively take dalotamide, they can't be cured, but it can prolong the survival period of patients, alleviate their clinical symptoms and improve their quality of life to a great extent. This should be that bright sunshine.

The information in this article comes from the Internet and is not used as treatment advice or investment advice. If this article has an impact on your rights and interests or is interested in this product, please contact us in time so that we can provide you with more help